Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Using Wearable Inertial Sensors to Assess Mobility of Patients With Hematologic Cancer and Associations With Chemotherapy-Related Symptoms Before Autologous Hematopoietic Stem Cell Transplant: Cross-sectional Study.
Skiba MB, Harker G, Guidarelli C, El-Gohary M, Horak F, Roeland EJ, Silbermann R, Hayes-Lattin B, Winters-Stone K. Skiba MB, et al. Among authors: silbermann r. JMIR Cancer. 2022 Dec 8;8(4):e39271. doi: 10.2196/39271. JMIR Cancer. 2022. PMID: 36480243 Free PMC article.
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Costa LJ, et al. Among authors: silbermann r. Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27. Lancet Haematol. 2023. PMID: 37776872 Free PMC article. Clinical Trial.
Bone effects of cancer therapies: pros and cons.
Silbermann R, Roodman GD. Silbermann R, et al. Curr Opin Support Palliat Care. 2011 Sep;5(3):251-7. doi: 10.1097/SPC.0b013e328349c524. Curr Opin Support Palliat Care. 2011. PMID: 21768880 Review.
Mechanisms of multiple myeloma bone disease.
Galson DL, Silbermann R, Roodman GD. Galson DL, et al. Among authors: silbermann r. Bonekey Rep. 2012 Aug 1;1:135. doi: 10.1038/bonekey.2012.135. eCollection 2012. Bonekey Rep. 2012. PMID: 23951515 Free PMC article.
Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.
Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, Roodman GD, Kurihara N. Teramachi J, et al. Among authors: silbermann r. Leukemia. 2016 Feb;30(2):390-8. doi: 10.1038/leu.2015.229. Epub 2015 Aug 19. Leukemia. 2016. PMID: 26286116 Free PMC article.
Myeloma bone disease: Pathophysiology and management.
Silbermann R, Roodman GD. Silbermann R, et al. J Bone Oncol. 2013 Apr 18;2(2):59-69. doi: 10.1016/j.jbo.2013.04.001. eCollection 2013 Jun. J Bone Oncol. 2013. PMID: 26909272 Free PMC article. Review.
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.
Storti P, Marchica V, Airoldi I, Donofrio G, Fiorini E, Ferri V, Guasco D, Todoerti K, Silbermann R, Anderson JL, Zhao W, Agnelli L, Bolzoni M, Martella E, Mancini C, Campanini N, Noonan DM, Petronini PG, Neri A, Aversa F, Roodman GD, Giuliani N. Storti P, et al. Among authors: silbermann r. Leukemia. 2016 Dec;30(12):2351-2363. doi: 10.1038/leu.2016.137. Epub 2016 May 20. Leukemia. 2016. PMID: 27311934
60 results